ADVERTISEMENTs
.png)
Ocuphire Pharma appoints two Indian Americans in leadership positions
Dr Ash Jayagopal is a bioengineer, and Nirav Jhaveri is a business professional.
.png)
Dr Ash Jayagopal (left) and Nirav Jhaveri (right) / (Image: LinkedIn)
Michigan-based clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. has appointed two Indian Americans to leadership positions.
As per the company's statement, Dr Ash Jayagopal was named chief scientific and development officer and Nirav Jhaveri as chief financial officer.
Expressing excitement about the appointment, Dr Jayagopal said, “I am excited to join the talented Ocuphire team that has a successful track record in drug development and execution. This is an exciting juncture at Ocuphire as the company continues to strengthen the retina pipeline by advancing APX3330 through clinical development for treating diabetic retinopathy.”
Jhaveri further noted, “I am thrilled to be joining a company that has the potential to be a leader in ophthalmology drug development. Ocuphire has demonstrated a commitment to addressing an unmet need in ophthalmic disease and I am eager to contribute to its success by helping the company advance to the next stage of growth.”
Commenting on the appointments, the company's chief executive officer, George Magrath, asserted, "Ash and Nirav are critical to our ability to continue progressing APX3330 and its analog compounds in our portfolio, beginning with our phase 3 program in diabetic retinopathy. I am excited to work alongside such a talented team and together to take on significant unmet medical needs with compelling science.”
Jayagopal is a bio-engineer with over 15 years of experience leading multidisciplinary research teams focused on therapeutic research and development, drug delivery platforms, and biomarkers for retinal diseases in industry and academia. Before joining Ocuphire, he served at Opus Genetics, Kodiak Sciences, and Roche.
He also serves as a fellow of the Association for Research in Vision and Ophthalmology (ARVO) and president of the Association for Ocular Pharmacology and Therapeutics (AOPT). At the same time, he serves on the Innovation Advisory Council for Foundation Fighting Blindness and the editorial board of the Journal of Ocular Pharmacology and Therapeutics.
Jhaveri, on the other hand, brings over 20 years of experience in valuation, business development, and capital markets to the biopharma industry. Before joining Ocuphire, he served at Insilico Medicine, Journey Medical Corporation, and Fortress Biotech.
He has held multiple financial markets roles, including in equity research at Citigroup and investment banking at Bank of America. The chartered financial analyst (CFA) has completed an MBA from New York University's Stern School of Business and a bachelor's degree in chemistry and economics from the University of Pennsylvania.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
.png)
.png)
.png)
.jpeg)
.jpg)
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login